Amicus Therapeutics, Inc. (FOLD)

NASDAQ:
FOLD
| Latest update: Mar 15, 2026, 7:49 PM

Price Chart

$14.37

0.00%
(1 month)

Top Shareholders

BlackRock, Inc.
10.52%
The Vanguard Group, Inc.
9.61%
HBK Partners II LP
4.93%
Avoro Capital LP
4.89%
State Street Corp.
4.80%
Pentwater Partners LP
3.72%
Bellevue Group AG
3.47%
WBC Holdings LP
3.44%

Sentiment for FOLD

News
Social

Buzz Talk for FOLD

Today

Social Media

General

Stock events for Amicus Therapeutics, Inc. (FOLD)

Amicus Therapeutics' stock has shown an upward trajectory, with a 77.48% increase over the past six months and a 57.76% increase over the past year. Key events include the proposed acquisition by BioMarin for $14.50 per share, strong financial results with a 23.7% year-over-year revenue increase in 2025, pipeline progress with DMX-200, and a consensus "Buy" rating from analysts with an average price target of $27.25.

Demand Seasonality affecting Amicus Therapeutics, Inc.’s stock price

The provided search results do not contain specific information regarding demand seasonality for Amicus Therapeutics, Inc.'s products and services. Demand for its treatments is driven by patient diagnosis and medical need rather than seasonal fluctuations. Consistent growth in product sales, driven by new patient starts and strong compliance, suggests a steady demand pattern.

Overview of Amicus Therapeutics, Inc.’s business

Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. Key products include Galafold for Fabry disease, Pombiliti + Opfolda for late-onset Pompe disease, and DMX-200 for FSGS kidney disease. The company also has a pipeline of gene therapies and combination therapies.

FOLD’s Geographic footprint

Amicus Therapeutics discovers, develops, and delivers medicines in the United States and internationally. Galafold is approved and marketed in the United States, European Union, and other territories. The company maintains research and development operations in multiple locations across the United States and Europe.

FOLD Corporate Image Assessment

Amicus Therapeutics maintains a strong brand reputation within the rare disease community due to its patient-dedicated approach. The successful commercialization of Galafold and Pombiliti + Opfolda, advancements in the clinical pipeline, and the strategic acquisition by BioMarin have positively affected the company's reputation.

Ownership

Amicus Therapeutics has a diverse ownership structure, with institutional investors holding a significant portion of the stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Perceptive Advisors LLC, which is the largest individual shareholder. Insiders have sold more stock than they have bought in the past three months.

FAQ

What is the current stock price of Amicus Therapeutics, Inc.?

As of the latest update, Amicus Therapeutics, Inc.'s stock is trading at $14.37 per share.

What’s happening with Amicus Therapeutics, Inc. stock today?

Today, Amicus Therapeutics, Inc. stock is stable by 0.00%, possibly due to news.

What is the market sentiment around Amicus Therapeutics, Inc. stock?

Current sentiment around Amicus Therapeutics, Inc. stock is negative, based on recent news, trading volume, and analyst opinions.

Is Amicus Therapeutics, Inc.'s stock price growing?

Over the past month, Amicus Therapeutics, Inc.'s stock price has unknown by 0.00%.

How can I buy Amicus Therapeutics, Inc. stock?

You can buy Amicus Therapeutics, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol FOLD

Who are the major shareholders of Amicus Therapeutics, Inc. stock?

Major shareholders of Amicus Therapeutics, Inc. include institutions such as BlackRock, Inc. (10.52%), The Vanguard Group, Inc. (9.61%), HBK Partners II LP (4.93%) ... , according to the latest filings.